Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

Heather S. Jim, PhD
Published: Tuesday, Sep 13, 2016


Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as treatment for patients with prostate cancer.

Androgen-deprivation therapy is associated with several side effects that include depression, cognitive impairment, fatigue, loss of muscle mass, and inflammation, as well as cardiovascular disease and cardiovascular mortality, Jim explains.

Regarding depression, research out of Moffitt Cancer Center suggests that 40% of patients experience clinically significant depressive symptoms after approximately 6 months of ADT. Jim adds that it is important to treat depression not only to help patients feel better, but because depression is associated with increased mortality in patients with prostate cancer.

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as treatment for patients with prostate cancer.

Androgen-deprivation therapy is associated with several side effects that include depression, cognitive impairment, fatigue, loss of muscle mass, and inflammation, as well as cardiovascular disease and cardiovascular mortality, Jim explains.

Regarding depression, research out of Moffitt Cancer Center suggests that 40% of patients experience clinically significant depressive symptoms after approximately 6 months of ADT. Jim adds that it is important to treat depression not only to help patients feel better, but because depression is associated with increased mortality in patients with prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x